VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

PUDUCHERRY: In a major breakthrough, researchers at Pondicherry University have identified molecular markers in tear fluid ...

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

Kodiak Sciences Inc.’s KOD share price has dipped by 10.63%, which has investors questioning if this is right time to buy.

India holds the unenviable position of being home to the world’s largest diabetic population, with nearly 100 million ...

Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...

Company management will be available for one-on-one meetings during the conference. If you are interested in arranging a meeting, please contact your conference representative or send an email to ...

Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supple ...

In December 2024, we reached agreement with the FDA under a SPA for a Phase 3 clinical trial evaluating APX3330, a novel, oral REF-1 inhibitor for the treatment of moderate to severe non-proliferative ...

About one-third to one-half of diabetics suffer from organ and tissue damage as a result of the disease’s strong correlation with both microvascular and macrovascular complications such as retinopathy ...